


## About The Company

---

CCC Diagnostics was formed in 2004 by a core group of former researchers at the Johns Hopkins University, providing over ninety years of leadership and discovery in biophysics, oncology, and imaging. The company is located in the Caton Research Center in Baltimore, MD.



## References

---

K. H. Tkaczuk, N. S. Tait, O. Ioffe, M. Tan, M. Mohiuddin, S. Chumsri, D. A. Van Echo, M. J. Sutula, S. Lesko, S. Deamond, P. Ts'o; Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). Clin Oncol 27:15s, 2009 (suppl; abstr 1119) – ASCO 2009.

K.H. Tkaczuk, N.S. Tait, W. Rodgers, M. Tan, O. Ioffe, S.A. Lesko, S. Deamond, Z.P. Lum, P.O.P. Ts'o. A Retrospective Study of the Drug Response Indicator Test (DRIT) as a Predictive Test for Therapeutic Outcomes of Advanced Breast Cancer Patients. 2008 San Antonio Breast Cancer Symposium, San Antonio, TX.

## Company Mission

---

CCC Diagnostics' mission is to lead the evolution in targeted cancer treatment by providing physicians with the most accurate cancer diagnostic tests predicting tumor response therapies.

---



Caton Research Center  
3918 Vero Road, Suite B  
Baltimore, MD 21227

Phone (410) 633-4885 x1000  
Fax (410) 633-4502  
[www.directhittest.com](http://www.directhittest.com)

CLIA #21D1043279  
Medical Lab Permit #1274  
NPI #1265685440

## Insurance and Medicare

---

CCC Diagnostics participates with many national and local health plans. Verification of the patient's insurance coverage and the contractual status of each policy is the responsibility of the ordering physician or facility prior to sample submission. For all contract billing questions, please contact Account Resolutions, LLC at (800) 799-5916.



## Health Professionals Brochure

---

The DirectHit Test Panel for Breast Cancer can predict, with a high degree of accuracy, a tumor's responsiveness to four distinct classes of commonly prescribed anti-cancer drugs. DirectHit is a diagnostic service performed on formalin fixed paraffin embedded tumor tissue removed during surgery. When used in combination with standard measurements, DirectHit allows physicians to avoid ineffective therapy and design an individualized chemotherapy treatment plan for each patient.

---

**DirectHit® is a registered trademark of CCC Diagnostics for the Drug Response Indicator Test (DRIT).**

# DirectHit Test Panel for Breast Cancer

---

The DirectHit Test Panel for Breast Cancer is a group of molecular pharmacodiagnostic tests performed on tumor sections which detects the sensitivity or resistance of breast tumors to specific drug regimens. Currently, our DirectHit Test Panel for Breast Cancer is the only predictive test marketed for commonly prescribed breast cancer chemotherapy drugs.

DirectHit targets sensitivity to the following drug classes: taxanes/vinca alkaloids, antiestrogens, trastuzumab and 5-FU/capecitabine. Expansion of the panel to include anthracyclines, gemcitabine, and platinum salts is in development.

DirectHit measures biomarkers mechanistically linked to the method of action of the targeted drug, using quantitative immunofluorescence to assess biomarker expression. Computerized microscopic analysis of the observed fluorescence quantitatively predicts the clinical benefit for a specific drug regimen for an individual breast cancer patient.

## Sample Requirements

---

Each DirectHit Test Panel requires six slides prepared from formalin fixed paraffin embedded tumor tissue. Please contact CCC Diagnostics' technical staff regarding sample preparation requirements.  
(410) 633-4885 ext. 1000

### Currently Available Tests:

- Breast Cancer

### Tests in Development:

- Gastrointestinal Cancer
- Lung Cancer

## Ordering DirectHit

---

Physicians should first establish an account with CCC Diagnostics by calling our Customer Service Line at (410) 633-4885 ext. 1000.

Next, schedule the test at the same number. CCC Diagnostics will send a sample kit for secure shipment of tumor slides. The turnaround time for the DirectHit Test Panel for Breast Cancer is six business days from the scheduled sample testing date.

For additional information and details on ordering the DirectHit Test Panel for Breast Cancer, call us at (410) 633-4885 ext. 1000 or visit our website at [directhittest.com](http://directhittest.com)



## The DirectHit Advantages

---

- Predicts efficacy of chemotherapy.
- Has quick turnaround time.
- Helps physician create individualized treatment plan.
- Improves quality of life by eliminating most ineffective drug treatments and their attendant side effects.
- Saves money.
- Participates with many national and local health plans.

## Management

---

### David A. Van Echo, M.D.

#### Medical Director

Dr. Van Echo was a principal researcher at NCI, headed the New Drug Development program at the University of Maryland Greenebaum Cancer Center and is currently the Director of the HarborView Cancer Center of the Harbor Hospital in Baltimore, Maryland. Dr. Van Echo received his M.D. from the University of Maryland School of Medicine.

### Stephen A. Lesko, Ph.D.

#### Research Director

Dr. Lesko was a faculty member of the Johns Hopkins University School of Public Health for over twenty years and is one of the foremost authorities in microscopy. He was instrumental in developing the computer-assisted imaging system for research applications at the Johns Hopkins University School of Public Health in 1981. Dr. Lesko received his doctorate in biochemistry from the University of Maryland, Baltimore.

### Vivian Lauderdale, MS, MBA, RAC

#### Chief Regulatory Officer

Ms. Lauderdale has an MS in biochemistry from George Washington School of Medicine, an Executive MBA from the Anderson School of Management at the University of California at Los Angeles, and a Medical Regulatory Affairs Certification through the Regulatory Affairs Professionals Society. She has over twenty years of experience in medical biotechnology product development, operations, and regulatory affairs.